NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides, Inc. (NYSE American: NNVC) will hold its Annual Shareholders Meeting at 10 a.m. on Saturday, November 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. The announcement comes as the clinical-stage company continues development of its broad-spectrum antiviral drug platform targeting multiple viral diseases.
The company's lead drug candidate, NV-387, represents a significant advancement in antiviral therapy with planned development for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX and smallpox infections. This broad-spectrum approach could potentially address multiple public health threats with a single therapeutic platform. The company is currently focused on advancing NV-387 into Phase II human clinical trials, though it cannot project exact dates for Investigational New Drug (IND) filings due to dependence on external collaborators and consultants.
Another advanced candidate in the pipeline is NV-HHV-1 for shingles treatment, expanding the company's reach beyond respiratory diseases. The company's technology platform, licensed from TheraCour Pharma, Inc., enables the creation of special purpose nanomaterials designed to prevent viral escape, a common challenge in antiviral drug development. The company holds exclusive, sub-licensable licenses for multiple viral diseases including HIV/AIDS, hepatitis B and C, rabies, herpes viruses, influenza, dengue, Ebola, and coronaviruses.
The company's business model, established at its foundation in 2005, involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. Additional information about the company is available at https://www.nanoviricides.com. The company also maintains that successful laboratory results against coronavirus do not guarantee successful clinical trials or pharmaceutical product development, highlighting the inherent risks in drug development that require substantial capital and face lengthy regulatory pathways.
Investors can access the latest news and updates relating to NNVC in the company's newsroom at https://ibn.fm/NNVC. The shareholder meeting announcement provides investors with an opportunity to engage with management as the company progresses its diverse pipeline of antiviral candidates targeting some of the world's most challenging viral diseases.